— Know what they know.
Not Investment Advice
Also trades as: ROG.SW (SIX) · $vol 450M · ROP.SW (SIX) · $vol 427M · RHHBY (OTC) · $vol 130M · RO.SW (SIX) · $vol 16M · 0QQ6.L (LSE) · $vol 4M · RHHBF (OTC) · $vol 0M

RHHVF OTC

Roche Holding AG
1W: +6.7% 1M: +21.4% 3M: +2.6% YTD: +11.6% 1Y: +46.5% 3Y: +55.1% 5Y: +56.9%
$450.50
+10.50 (+2.39%)
 
Weekly Expected Move ±7.1%
$368 $399 $430 $460 $491
OTC · Healthcare · Drug Manufacturers - General · Alpha Radar Buy · Power 69 · $310.4B mcap · 565M float · 0.0005% daily turnover · Short 44% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$310.4B
52W Range300.15-490.33
Volume301
Avg Volume2,640
Beta0.60
Dividend$12.41
Analyst Ratings
3 Buy 5 Hold 1 Sell
Consensus Hold
Company Info
CEOThomas Schinecker
Employees103,249
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2009-02-13
Websiteroche.com
Grenzacherstrasse 124
Basel 4070
CH
41 61 688 11 11
About Roche Holding AG

Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United States, in addition to its broader international footprint. Its extensive pharmaceutical division develops and offers treatments for a diverse range of conditions. These therapeutic areas encompass critical fields such as oncology (cancer), neuroscience, infectious diseases, immunology, hemophilia, ophthalmology (eye care), dermatology (skin conditions), respiratory illnesses, anemia, inflammatory and autoimmune disorders, and transplantation. Beyond medicinal products, Roche is also a prominent supplier of in vitro diagnostic tests. These tests are vital for identifying numerous diseases, including various cancers, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Complementing its testing services, the company provides the essential diagnostic instruments and chemical reagents necessary for these procedures. Demonstrating its commitment to innovation, Roche has established a research partnership with Synlogic, Inc. This collaboration aims to discover a novel synthetic biotic designed specifically for the treatment of inflammatory bowel disease (IBD). Tracing its origins back to its founding in 1896, Roche Holding AG is headquartered in Basel, Switzerland.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms